Yvonne L. Greenstreet, M.D.

Yvonne L. Greenstreet, M.D.

Chief Executive Officer (principal executive officer)atAlnylam Pharmaceuticals· In proxies 2022–2025

Pay in FY2025+29% from the year before · Alnylam Pharmaceuticals stock +69.0% the same year

Yvonne L. Greenstreet, M.D. was paid $14.9M in FY2025 (Dec), up 29%. Alnylam Pharmaceuticals stock rose 69.0% that year.

Pay$100 in the stock at the end of FY21 → $234
Pay is from the Summary Compensation Table of each Alnylam Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Alnylam PharmaceuticalsPublic company · 4 yr
    • Chief Executive Officer (principal executive officer)2022 – Present · 4 yrStock in role +44%
  2. Vir Biotechnology, Inc.Public company
    • Director? – PresentNo stock prices for these years
  3. Adaptimmune TherapeuticsPublic company
    • Director? – PresentNo stock prices for these years
  4. Surface Oncology Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?